Cybin: Changing Mental Healthcare with Psychedelics

Novel psychedelic therapies

Cybin is on a mission to revolutionize mental healthcare. They’re focusing on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches as well as treatment regimens for psychiatric disorders.

Moreover, Cybin is striving to make novel psychedelic therapies available and convenient for all patients seeking treatment for mental illness. This is done through wide access and practical treatment duration to improve compliance.

Psychedelic therapies offer a novel approach to mental healthcare. They’re focused on treating the underlying conditions and improving the patient experience and outcome. A paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens.

Cybin is at the forefront of this revolution. Further, they believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape. While psychedelics may represent a new industry, Cybin recognizes the long history of use within indigenous cultures and major scientific breakthroughs over the decades that have led us to where we are today. Additionally, the company is well funded to start clinical trials.

For more information on Cybin Inc. (NEO: CYBN, NYSE AMERICAN: CYBN) please click the request investor info button.